[Metabolic syndrome and prediabetic states]
P Galajda1, Michal Mokáň, Marián Mokáň
1Interná klinika Jesseniovej lekárskej fakulty UN Martin, Slovenská Republika. galajda@lefa.sk
Vnitrni Lekarstvi
|July 2, 2013
Summary
Metabolic syndrome involves insulin resistance, obesity, and abnormal lipid levels, increasing risks for heart disease and type 2 diabetes. Lifestyle changes and medications like metformin can help prevent type 2 diabetes, though statins may slightly raise risk.
Area of Science:
- Endocrinology
- Cardiology
- Metabolic Diseases
Background:
- Metabolic syndrome is a cluster of risk factors including insulin resistance, central obesity, atherogenic dyslipidemia, and hypertension.
- These factors significantly increase the risk of coronary heart disease and type 2 diabetes mellitus (DM2).
- Prediabetic states, characterized by impaired glucose metabolism, are key components.
Purpose of the Study:
- To define metabolic syndrome and its associated prediabetic states.
- To discuss diagnostic methods for prediabetes, including HbA1c.
- To review prevention and treatment strategies for DM2 within the context of metabolic syndrome.
Main Methods:
- Diagnostic criteria for metabolic syndrome and prediabetes were reviewed.
- The role of fasting glucose, oral glucose tolerance tests, and HbA1c in diagnosis was discussed.
- Evidence for lifestyle interventions and pharmacotherapy in DM2 prevention was assessed.
Main Results:
- Metabolic syndrome includes impaired fasting glucose, impaired glucose tolerance, or elevated HbA1c, central obesity, dyslipidemia (high triglycerides, low HDL), and hypertension.
- Physical activity (≥30 min daily) is crucial for DM2 prevention.
- Metformin and certain antihypertensives (e.g., sartans) show efficacy in DM2 prevention.
- Statins for dyslipidemia may moderately increase DM2 risk in prediabetic individuals, but cardiovascular benefits can outweigh this.
Conclusions:
- Early diagnosis of prediabetic states is essential for managing metabolic syndrome.
- Lifestyle modification and targeted pharmacotherapy are key strategies for preventing type 2 diabetes.
- Risk-benefit assessment is crucial when using statins in patients with metabolic syndrome and prediabetes.
Related Concept Videos
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:24Metabolic States of the Body: Fasting and Starvation
During the initial hours of fasting, the body uses up its glycogen stores as an energy source. Once these glycogen reserves are depleted, the body begins breaking down stored triglycerides and structural proteins. During this stage, glycerol becomes a key substrate for gluconeogenesis, while free fatty acids undergo beta-oxidation to provide energy for tissues, such as skeletal muscle. In the fasting state, the body spares protein breakdown as much as possible to conserve muscle and structural...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:18Metabolic States of the Body: The Postabsorptive State
The postabsorptive state usually starts about four hours after a meal and lasts until the next meal is eaten. During this time, the digestive system stops absorbing nutrients, and the body uses stored energy reserves to maintain stable blood glucose levels.
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...